NCT01379001

Completed

Assessment of Cholinergic and Cognitive Function Using Pharm...

Hebrew SeniorLife Source

Compare

Other study identifiers

Sponsor study identifier

K23AG031320

NIH

Study Type

interventional

Actual enrollment (reported)

60

Locations

0 countries

Sites

N/A

Timeline

Study Start

July 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

January 2013

Actual (reported)

Study Completion

January 2013

Actual (reported)

Brief Summary

This research study will look at how medications affect the pattern of blood flow in the brain. This study will use a special type of MRI (magnetic resonance imaging) scan called perfusion MRI to make measurements of cerebral (brain) blood flow. The medications we will use in this study are scopolamine (commonly used to treat motion sickness), mecamylamine (used to treat high blood pressure), and donepezil (used to treat memory loss). Cognitive testing will also be obtained, and correlated with the blood flow patterns in the brain.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 60 participants
Study completion date: January 2013
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 2008
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
June 21, 2011
Actual (reported)
First Posted
June 23, 2011
Actual (reported)
Primary Completion
January 2013
Actual (reported)
Study Completion
January 2013
Actual (reported)

Last Updated: January 4, 2013
Status Verified: January 2013
Last Update Submitted: January 3, 2013

Conditions

Cholinergic Function

Keywords

cholinergic functionagingpharmacologic MRI

Outcome Measures

Primary Outcomes (1)

Cerebral blood flow
cerebral blood flow will be measured 3 hours after drug administration using Arterial spin-labeled perfusion MRI
3 hours

Secondary Outcomes (1)

cognitive performance
4 hours

Study Arms (2)

Young

EXPERIMENTAL

Young healthy controls, aged 21-35

Drug: ScopolamineDrug: Placebo

Older

EXPERIMENTAL

Older healthy controls, aged 65-80

Drug: ScopolamineDrug: PlaceboDrug: Donepezil

Interventions

ScopolamineDrug

Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)

OlderYoung

PlaceboDrug

IM or PO placebo

OlderYoung

Eligibility Criteria

Age21 Years - 80 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

healthy volunteers

You may not qualify if:

Sponsors & Collaborators

Hebrew SeniorLife
Otherlead

MeSH Terms

Interventions

ScopolamineDonepezil

Intervention Hierarchy (Ancestors)

Scopolamine DerivativesTropanesAzabicyclo CompoundsAza CompoundsOrganic ChemicalsBelladonna AlkaloidsSolanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsBridged Bicyclo Compounds, HeterocyclicHeterocyclic Compounds, Bridged-RingIndansIndenes

Study Officials

Tamara Fong, MD
Hebrew Rehabilitation Center
PRINCIPAL INVESTIGATOR

Enrollment

60 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, INVESTIGATOR
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Assistant Scientist/Assistant Professor of Neurology

Study Record Dates

First Submitted

June 21, 2011

First Posted

June 23, 2011

Study Start

July 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT00934531

Donepezil and the Risk of Falls in Seniors With Cognitive Impairment

Not ApplicableCompleted

NCT00533065

Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone

Not ApplicableCompleted

NCT00530478

Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment

Not ApplicableUnknown

NCT02273895

The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study

Not ApplicableCompleted

NCT01198106

A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness

Not ApplicableUnknown

NCT00659737

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Not ApplicableCompleted

DonepezilDrug

donepezil 5mg PO x 1

Also known as: Aricept

Older

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Any neurological condition, such as brain tumor, history of stroke, seizure disorder, attention deficit disorder, normal pressure hydrocephalus, dementia, traumatic brain injury

Any major medical conditions, such a cancer, diabetes, glaucoma, prostate disease, uncontrolled hypertension

antihistamine use

tricyclic antidepressant use

presence of metal in body, including pacemaker, defibrillator, neurostimulator, metal implants, or foreign metal objects such as bullets or shrapnel.

anxiety or panic disorder

history of claustrophobia

pregnancy

Contact the study team to confirm eligibility.

Polycyclic Aromatic Hydrocarbons

Hydrocarbons, Aromatic

Hydrocarbons, Cyclic

Hydrocarbons

Piperidines

Heterocyclic Compounds, 1-Ring

Polycyclic Compounds

Primary Completion

January 2013

Actual (reported)

Study Completion

January 2013

Actual (reported)

Last Updated

January 4, 2013

Record last verified: 2013-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01379001
Data provider: ClinicalTrials.gov
Source updated: 2013-01-04
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:08 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Young

Older

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record